A phase 2, randomized, double-blind, placebo-controlled, flexible escalating -dose, pilot analgesic efficacy study of T-62 in subjects with postherpetic neuralgia

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled, flexible escalating -dose, pilot analgesic efficacy study of T-62 in subjects with postherpetic neuralgia

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs T 62 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2012 Company (Pfizer) added to the associations field as reported by ClinicalTrials.gov record.
    • 13 Nov 2007 Status changed from recruiting to withdrawn prior to recruitment.
    • 20 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top